摘要
目的 检测肺腺癌病人化疗前后血清可溶性Fas（sFas）水平探讨其临床意义。方法 应用酶联免疫吸附试验法（ELISA）检测60例肺腺癌病人化疗前后血清sFas水平并同时检测30例正常人血清sFas水平作对比分析。结果 肺腺癌病人血清sFas水平明显高于正常对照组（P〈0．01）。血清sFas水平与临床分期有关，与肺腺癌病人性别、年龄、细胞分化程度无关，Ⅳ期肺腺癌血清sFas水平明显高于Ⅲ期和Ⅱ期（P〈0．01），Ⅲ期明显高于Ⅱ期（P〈0．01），化疗后有效（完全缓解和部分缓解）病人血清sFas水平明显低于化疗前（P〈0．01）。结论 血清sFas与肺腺癌的发生及发展有一定关系，检测血清sFas有可能成为肺腺癌辅助诊断、病情发展及化疗疗效观察的一项有价值的指标。
Objective To analyse the levels of soluble Fas （sFas） before and after therapy of Vinorelbine combined with cisplatin in patients with lung adenocarcinoma and its clinical significance. Methods Enzyme linked immunosorbent assays （ELISA） was used to detect the level of sFas in 60 case of patients with lung adenocarcinoma before and after chemotherapy and 30 case of normal persons used as normal control subjects. Results Levels of sFas were elevated in both groups before and after chemotherapy of patients with lung adenocarcinoma as compared with the control group （P〈0.01）. The level of sFas was correlated with clinical stage, but not with sex, age and histological grade ; The sFas level in stage Ⅳ was higher than that in stage Ⅲ and Ⅱ （P〈0.01）, and that in stage Ⅲ was higher than that in stage Ⅱ （P〈0.01）. And it was remarkably reduced in complete remission or partial remission periods patients after chemotherapy （P〈0.01）. Conclusion The elevation of sFas were correlated with progression of lung adenocarcinoma and it may be used as a criterion in the diagnosis and the progress of the disease as well as in evaluating the curative effects of chemotherapy in patients with lung adenocarcinoma.
出处
《世界肿瘤杂志》
2005年第4期265-267,共3页
Tumour Journal of the World
